CBLL
Ceribell, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$28.11
−0.57%Year over year
Reported trailing growth
- Revenue
- +31.3%
- EBITDA
- -44.5%
- EBIT
- -33.8%
- EPS
- -28.5%
- Free cash flow
- -37.4%
- Operating cash flow
- -40.0%
Forward estimates
Based on analyst estimates
- Revenue
- +27.8%
- EBITDA
- +14.1%
- EPS
- +13.4%
Three-year CAGR
- Revenue
- +50.9%
- EBITDA
- -34.5%
- EBIT
- -47.1%
- Net income
- -32.0%
- EPS
- -29.2%
- Free cash flow
- -14.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026